TELA Bio, Inc.
TELA Bio, Inc. scores highest on Nitro (66) and lowest on Price (0). Its PosiPenta is 32.25 out of 100, weaker than most similar companies.
On the Penta Grid this week, TELA Bio, Inc. is Grid #724 of 837 in the Healthcare sector in United States, and Grid #3,479 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| TELA Bio, Inc. | 32.25 | 0 | 53 | 66 | 2 | 41 |
| SANUWAVE Health, Inc. | 26.24 | 34 | 43 | 20 | 3 | 32 |
| Envoy Medical, Inc. | 44.88 | 5 | 60 | 72 | 41 | 45 |
| ImageneBio, Inc. | 40.29 | 48 | 19 | 32 | 53 | 49 |
| Precision Optics Corporation, Inc. | 55.61 | 25 | 73 | 65 | 53 | 61 |
| Serina Therapeutics, Inc. | 39.58 | 26 | 43 | 34 | 28 | 66 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -1.27 |
| P/B ratio | -2.77 |
EEarnings
| Trailing EPS | ₹-72.93 |
| Forward EPS | ₹-42.62 |
NNitro
| Price | 92.35 |
| 52-week high | 147.76 |
| 52-week low | 47.45 |
| Fall from 52-week high | 37.5% |
TTorque
| Return on equity (ROE) | — |
| Debt-to-equity | 8.90 |
AAnchor
| Beta (price swings) | 1.36 |
| Market cap | ₹416 Cr |
| Insider holding | 7.11% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is TELA Bio, Inc.'s PosiPenta score?
TELA Bio, Inc.'s PosiPenta is 32.25 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does TELA Bio, Inc. stand on the Penta Grid?
On the Penta Grid this week, TELA Bio, Inc. is Grid #724 of 837 in the Healthcare sector in United States, and Grid #3,479 of 4,000 in United States.
Which PosiPenta pillar is strongest for TELA Bio, Inc.?
Nitro (momentum), with a score of 66 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for TELA Bio, Inc.?
Price (valuation), with a score of 0 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.